Vol. 1, Issue 1, Part A (2019)

Abstract: Phenothiazines (PZNs) are a class of drugs that have significant in vitro activity against susceptible, polydrug- and MDR strains of Mtb, as well as enhancing the activity of some drugs used for first-line treatment. The PZNs have the potential as an adjunct to conventional drug therapy during the lengthy period before antibiotic susceptibility data are available. They may reduce morbidity associated with the use of Rifampicin and Streptomycin by allowing their use in lower dosages. The need for new and effective anti-TB drugs is recognized, PZNs are hope against MDR-TB, whether less toxic PZN may be exploited as an anti-TB agent. The role of PZN analogs as an adjunct drug in the therapy of tubercular and MDR-TB.